ROCKIF trial of defactinib in ovarian cancer terminated for lost funding; results posted
The Phase 1/2 ROCKIF study testing defactinib with carboplatin and paclitaxel in platinum-resistant ovarian cancer ended early, with results posted after study completion.
The main development is the closeout of a small combination trial in recurrent ovarian cancer.
- The "ROCKIF Trial" (NCT03287271), a Phase 1/2 study of defactinib (VS-6063) added to carboplatin and paclitaxel, was terminated with the study aiming to investigate the combination VS-6063, carboplatin, and paclitaxel in the treatment of patients with ovarian cancer.1 The trial's overall status shows it was terminated, with the reason given as loss of funding.1
- Enrollment reached 8 participants across defactinib doses of 200 mg and 400 mg combined with carboplatin and paclitaxel.1
- The study opened on an actual start date of 2018-02-06, with primary completion on 2023-07-30 and study completion on 2025-03-12.1 Results were first posted on 2026-07-31, the same day as the last update.
- Verastem, Inc. and Nine Girls Ask are listed as collaborators, with Michael McHale serving as lead sponsor.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.